Turnstone Biologics Raises $80 Million Series D Financing

Ontario Industry Updates
Written By Doriane Rey
Turnstone Biologics.png

Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, recently announced the successful completion of an $80 million Series D financing co-led by PFM Health Sciences and Point72.

Doriane Rey
Previous

Lumira raises $220-million for Canadian biotech fund
Next

Think Research Announces Definitive Agreement to Acquire BioPharma, a Leading Global Clinical Research Organization